FOLD Quote, Financials, Valuation and Earnings

Immuneering has a net margin of 9.85% compared to Amicus Therapeutics's net margin of --. Amicus Therapeutics's return on equity of -35.23% beat Immuneering's return on equity of --.

Amicus Therapeutics has a consensus price target of $16.73, signalling upside risk potential of 89.87%. On the other hand Immuneering has an analysts' consensus of $11.92 which suggests that it could grow by 673.81%. Given that Immuneering has higher upside potential than Amicus Therapeutics, analysts believe Immuneering is more attractive than Amicus Therapeutics.

Amicus Therapeutics has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison Immuneering has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Immuneering pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $149.7M, which are larger than Immuneering quarterly revenues of --. Amicus Therapeutics's net income of $14.7M is higher than Immuneering's net income of -$14.6M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Immuneering's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 5.08x versus 143.51x for Immuneering. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of 9.85% compared to Amicus Therapeutics's net margin of -225.53%. Amicus Therapeutics's return on equity of -35.23% beat Insmed's return on equity of -41989.34%.

Amicus Therapeutics has a consensus price target of $16.73, signalling upside risk potential of 89.87%. On the other hand Insmed has an analysts' consensus of $95.66 which suggests that it could grow by 27.43%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

Amicus Therapeutics has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison Insmed has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.99%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $149.7M, which are larger than Insmed quarterly revenues of $104.4M. Amicus Therapeutics's net income of $14.7M is higher than Insmed's net income of -$235.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 5.08x versus 33.85x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of 9.85% compared to Amicus Therapeutics's net margin of -30.91%. Amicus Therapeutics's return on equity of -35.23% beat PTC Therapeutics's return on equity of --.

Amicus Therapeutics has a consensus price target of $16.73, signalling upside risk potential of 89.87%. On the other hand PTC Therapeutics has an analysts' consensus of $64.93 which suggests that it could grow by 22.25%. Given that Amicus Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Amicus Therapeutics is more attractive than PTC Therapeutics.

Amicus Therapeutics has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.007%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $149.7M, which are smaller than PTC Therapeutics quarterly revenues of $213.2M. Amicus Therapeutics's net income of $14.7M is higher than PTC Therapeutics's net income of -$65.9M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 5.08x versus 5.03x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of 9.85% compared to Amicus Therapeutics's net margin of -9.24%. Amicus Therapeutics's return on equity of -35.23% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Amicus Therapeutics has a consensus price target of $16.73, signalling upside risk potential of 89.87%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 157.45%. Given that Vanda Pharmaceuticals has higher upside potential than Amicus Therapeutics, analysts believe Vanda Pharmaceuticals is more attractive than Amicus Therapeutics.

Amicus Therapeutics has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.079%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $149.7M, which are larger than Vanda Pharmaceuticals quarterly revenues of $53.2M. Amicus Therapeutics's net income of $14.7M is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 5.08x versus 1.44x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.